eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Archimedes Pharma UK Ltd

250 South Oak Way, Green Park, Reading, RG2 6UG, UK
Telephone: +44 (0)118 931 5050
Fax: +44 (0)118 931 5056
WWW: http://www.archimedespharma.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 03/11/2010
SPC Pabrinex Intramuscular High Potency Injection


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Pabrinex Intramuscular High Potency, Solution for injection


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each presentation (carton) contains either 5ml or 2ml ampoules. Each pair of ampoules to be used in treatment is labelled Pabrinex No 1 and Pabrinex No 2.

Each No. 1 ampoule contains: 5ml ampoule
Thiamine Hydrochloride BP250mg
Riboflavin (as Phosphate Sodium BP)4mg
Pyridoxine Hydrochloride BP50mg
Each No. 2 ampoule contains:2ml ampoule
Ascorbic acid BP500mg
Nicotinamide BP160mg

For a full list of excipients, see section 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Solution for injection.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C, particularly in alcoholism, after acute infections, post-operatively and in psychiatric states.


Go to top of the page
4.2 Posology and method of administration

Pabrinex is also available as an Intravenous High Potency Injection. Therefore before administration ensure that both the Summary of Product Characteristics and ampoule labels refer to the INTRAMUSCULAR injection.

The contents of one ampoule number 1 and one ampoule number 2 of Pabrinex Intramuscular High Potency (total 7ml) are drawn up into a syringe to mix them just before use, then injected slowly high into the gluteal muscle, 5cm below the iliac crest.

Adults: The contents of one pair of ampoules (7ml) twice daily for up to 7 days.

Elderly: As for adults.

Children: Pabrinex Intramuscular High Potency is rarely indicated for administration to children, however suitable doses are as follows:

Under 6 years

quarter of the adult dose

6-10 years

third of the adult dose

10-12 years

half to two thirds of the adult dose

14 years and over

as for the adult dose


Go to top of the page
4.3 Contraindications

Known hypersensitivity to any of the active constituents or to the excipients.


Go to top of the page
4.4 Special warnings and precautions for use

Although potentially serious allergic adverse reactions such as anaphylactic shock may occur rarely during, or shortly after, parenteral administration of Pabrinex Intramuscular, such rare occurrence of serious allergic reactions should not preclude the use of Pabrinex Intramuscular in patients who need treatment by this route of administration. Initial warning signs of a reaction to Pabrinex Intramuscular are sneezing or mild asthma, and those treating patients need to note that the administration of further injections to such patients may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex Intramuscular High Potency is administered.

This medicine is for injection into a muscle only and should not be given by any other route

Care should be taken to ensure that the route of administration used (intramuscular or intravenous) is that intended – reports of unintentional administration by the wrong route have been received; these incidents have not been associated with serious adverse reactions.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

The content of pyridoxine may interfere with the effects of concurrent levodopa therapy.


Go to top of the page
4.6 Pregnancy and lactation

No adverse effects have been noted at recommended doses when used as clinically indicated.

However animal studies are insufficient with respect to effects on pregnancy/ and-or/ embryonal/foetal development/ and-or/ parturition/ and-or/ postnatal development (see section 5.3). The potential risk for humans is unknown.

Caution should be exercised when prescribing to pregnant women.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

Occasionally, hypotension and mild paraesthesia from continued high doses of thiamine; occasionally mild ache at local site of injection.


Go to top of the page
4.9 Overdose

In the unlikely event of over dosage, treatment is symptomatic and supportive.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pabrinex Intramuscular High Potency contains vitamins B1, B2, B6, nicotinamide and vitamin C.

ATC code: A11EB


Go to top of the page
5.2 Pharmacokinetic properties

None supplied.


Go to top of the page
5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the Summary of Product Characteristics.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Edetic acid

Sodium hydroxide

Benzyl alcohol

Water for Injections


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

24 months.


Go to top of the page
6.4 Special precautions for storage

Store in a refrigerator at 2°C to 8°C. Keep the container in the outer carton. Do not freeze.


Go to top of the page
6.5 Nature and contents of container

Pabrinex Intramuscular High Potency is supplied in pairs of (5ml and 2ml) amber glass ampoules in packs of 10 pairs.


Go to top of the page
6.6 Special precautions for disposal and other handling

In common with all parenteral products each ampoule should be visually inspected prior to administration and should not be used if particulates are present.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Archimedes Pharma UK Limited

250 South Oak Way

Green Park

Reading

Berkshire

RG2 6UG

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 12406/0004


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: October 1993

Date of the latest renewal: October 2003


Go to top of the page
10. DATE OF REVISION OF THE TEXT

22 July 2010



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/6570/SPC/


Active Ingredients/Generics

 
   ascorbic acid
   pyridoxine
   nicotinamide
   thiamine
   riboflavin